Two strategies toward therapy in the psap KO model. (A) Three treatment schemes in the psap KO model. (B) qRT-PCR of mbpa, tnfb, il1b, nfkbiaa and cd68 in 33 dpf WT (n=9), untreated psap+63/+63 (n=11), and MMF-treated psap+63/+63 (n=10) zebrafish brains. Data show the mean±s.e.m. Two-tailed unpaired Student's t-test was used. NS, not significant; ***P<0.001. (C) Survival analysis of WT (n=37), untreated psap+63/+63 (n=33) and MMF-treated psap+63/+63 (n=31) zebrafish starting from 3 mpf. Log-rank (Mantel–Cox) test was used. Results were not significantly different for KO versus KO+MMF; P<0.001 for WT versus KO and WT versus KO+MMF. (D) Survival analysis of psap+63/+63, smpd1+/+ (KO/WT, black line) (n=19); psap+63/+63, smpd1−20/+ (KO/het, gray line) (n=59); and psap+63/+63, smpd1−20/−20 (KO/KO, red line) (n=25) zebrafish starting from 3 mpf. Log-rank (Mantel–Cox) test was used. Results were not significantly different for KO/WT versus KO/het and KO/KO versus KO/het. **P<0.01 for KO/WT vs KO/KO.
|